Search

Your search keyword '"Heizmann, Marc"' showing total 17 results
Start Over Author "Heizmann, Marc"
17 results on '"Heizmann, Marc"'

2. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

Author

Kennedy, Vanessa E., Perkins, Cecelia, Reiter, Andreas, Jawhar, Mohamad, Lübke, Johannes, Kluin-Nelemans, Hanneke C., Shomali, William, Langford, Cheryl, Abuel, Justin, Hermine, Olivier, Niedoszytko, Marek, Gorska, Aleksandra, Mital, Andrzej, Bonadonna, Patrizia, Zanotti, Roberta, Tanasi, Ilaria, Mattsson, Mattias, Hagglund, Hans, Triggiani, Massimo, Yavuz, Akif Selim, Panse, Jens, Christen, Deborah, Heizmann, Marc, Shoumariyeh, Khalid, Müller, Sabine, Elena, Chiara, Malcovati, Luca, Fiorelli, Nicolas, Wortmann, Friederike, Vucinic, Vladan, Brockow, Knut, Fokoloros, Christos, Papageorgiou, Sotirios G., Breynaert, Christine, Bullens, Dominique, Doubek, Michael, Ilerhaus, Anja, Angelova-Fischer, Irena, Solomianyi, Oleksii, Várkonyi, Judit, Sabato, Vito, Rüfer, Axel, Schug, Tanja Daniela, Hermans, Maud A. W., Fortina, Anna Belloni, Caroppo, Francesca, Bumbea, Horia, Gulen, Theo, Hartmann, Karin, Elberink, Hanneke Oude, Schwaab, Juliana, Arock, Michel, Valent, Peter, Sperr, Wolfgang R., and Gotlib, Jason

Published
2023
Full Text
View/download PDF

3. Mast cell leukemia:clinical and molecular features and survival outcomes of patients in the ECNM Registry

Author

Kennedy, Vanessa E., Perkins, Cecelia, Reiter, Andreas, Jawhar, Mohamad, Lübke, Johannes, Kluin-Nelemans, Hanneke C., Shomali, William, Langford, Cheryl, Abuel, Justin, Hermine, Olivier, Niedoszytko, Marek, Gorska, Aleksandra, Mital, Andrzej, Bonadonna, Patrizia, Zanotti, Roberta, Tanasi, Ilaria, Mattsson, Mattias, Hagglund, Hans, Triggiani, Massimo, Yavuz, Akif Selim, Panse, Jens, Christen, Deborah, Heizmann, Marc, Shoumariyeh, Khalid, Müller, Sabine, Elena, Chiara, Malcovati, Luca, Fiorelli, Nicolas, Wortmann, Friederike, Vucinic, Vladan, Brockow, Knut, Fokoloros, Christos, Papageorgiou, Sotirios G., Breynaert, Christine, Bullens, Dominique, Doubek, Michael, Ilerhaus, Anja, Angelova-Fischer, Irena, Solomianyi, Oleksii, Várkonyi, Judit, Sabato, Vito, Rüfer, Axel, Schug, Tanja Daniela, Hermans, Maud A.W., Fortina, Anna Belloni, Caroppo, Francesca, Bumbea, Horia, Gulen, Theo, Hartmann, Karin, Elberink, Hanneke Oude, Schwaab, Juliana, Arock, Michel, Valent, Peter, Sperr, Wolfgang R., Gotlib, Jason, Kennedy, Vanessa E., Perkins, Cecelia, Reiter, Andreas, Jawhar, Mohamad, Lübke, Johannes, Kluin-Nelemans, Hanneke C., Shomali, William, Langford, Cheryl, Abuel, Justin, Hermine, Olivier, Niedoszytko, Marek, Gorska, Aleksandra, Mital, Andrzej, Bonadonna, Patrizia, Zanotti, Roberta, Tanasi, Ilaria, Mattsson, Mattias, Hagglund, Hans, Triggiani, Massimo, Yavuz, Akif Selim, Panse, Jens, Christen, Deborah, Heizmann, Marc, Shoumariyeh, Khalid, Müller, Sabine, Elena, Chiara, Malcovati, Luca, Fiorelli, Nicolas, Wortmann, Friederike, Vucinic, Vladan, Brockow, Knut, Fokoloros, Christos, Papageorgiou, Sotirios G., Breynaert, Christine, Bullens, Dominique, Doubek, Michael, Ilerhaus, Anja, Angelova-Fischer, Irena, Solomianyi, Oleksii, Várkonyi, Judit, Sabato, Vito, Rüfer, Axel, Schug, Tanja Daniela, Hermans, Maud A.W., Fortina, Anna Belloni, Caroppo, Francesca, Bumbea, Horia, Gulen, Theo, Hartmann, Karin, Elberink, Hanneke Oude, Schwaab, Juliana, Arock, Michel, Valent, Peter, Sperr, Wolfgang R., and Gotlib, Jason

Abstract

Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis defined by ≥20% mast cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the European Competence Network on Mastocytosis registry. Thirty-one (34%) patients had a diagnosis of MCL with an associated hematologic neoplasm (MCL-AHN). Chronic MCL (lack of C-findings) comprised 14% of patients, and only 4.5% had “leukemic MCL” (≥10% circulating MCs). KIT D816V was found in 62/85 (73%) evaluable patients; 9 (11%) individuals exhibited alternative KIT mutations, and no KIT variants were detected in 14 (17%) subjects. Ten evaluable patients (17%) had an abnormal karyotype and the poor-risk SRSF2, ASXL1, and RUNX1 (S/A/R) mutations were identified in 16/36 (44%) patients who underwent next-generation sequencing. Midostaurin was the most common therapy administered to 65% of patients and 45% as first-line therapy. The median overall survival (OS) was 1.6 years. In multivariate analysis (S/A/R mutations excluded owing to low event rates), a diagnosis of MCL-AHN (hazard ratio [HR], 4.7; 95% confidence interval [CI], 1.7-13.0; P = .001) and abnormal karyotype (HR, 5.6; 95% CI, 1.4-13.3; P = .02) were associated with inferior OS; KIT D816V positivity (HR, 0.33; 95% CI, 0.11-0.98; P = .04) and midostaurin treatment (HR, 0.32; 95% CI, 0.08-0.72; P = .008) were associated with superior OS. These data provide the most comprehensive snapshot of the clinicopathologic, molecular, and treatment landscape of MCL to date, and should help further inform subtyping and prognostication of MCL.

Published
2023

6. Fungemia and necrotic lymph node infection with Sporopachydermia cereana in a patient with acute myeloid leukemia

Author

Kingston, Craig, primary, Medinger, Michael, additional, Banderet-Uglioni, Florian, additional, Bassetti, Stefano, additional, Bargetzi, Mario, additional, Haubitz, Sebastian, additional, Fux, Christoph A., additional, Bättig, Veronika, additional, Goldenberger, Daniel, additional, Passweg, Jakob, additional, and Heizmann, Marc, additional

Published
2017
Full Text
View/download PDF

8. Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

Author

Martinelli, Giovanni, primary, Hsu Schmitz, Shu-Fang, additional, Utiger, Urs, additional, Cerny, Thomas, additional, Hess, Urs, additional, Bassi, Simona, additional, Okkinga, Emmie, additional, Stupp, Roger, additional, Stahel, Rolf, additional, Heizmann, Marc, additional, Vorobiof, Daniel, additional, Lohri, Andreas, additional, Dietrich, Pierre-Yves, additional, Zucca, Emanuele, additional, and Ghielmini, Michele, additional

Published
2010
Full Text
View/download PDF

16. JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera.

Author

Röthlisberger, Benno, Huber, Andreas, Bargetzi, Mario, Mendez, Adriana, and Heizmann, Marc

Subjects
LETTERS to the editor, ERYTHROCYTE disorders
Abstract

A letter to the editor is presented in response to the previously published article on polycythermia vera and patients with idiopathic erythrocytosis.

Published
2008
Full Text
View/download PDF

17. Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions.

Author

O'Meara AC, Demarmels Biasiutti F, and Heizmann M

Subjects
Aged, Anticoagulants administration & dosage, Fondaparinux, Humans, Injections, Subcutaneous, Male, Nadroparin administration & dosage, Polycythemia Vera complications, Thromboembolism etiology, Treatment Outcome, Anticoagulants adverse effects, Drug Eruptions etiology, Hypersensitivity, Delayed chemically induced, Nadroparin adverse effects, Polycythemia Vera drug therapy, Polysaccharides therapeutic use, Thromboembolism prevention & control
Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results